Immune checkpoint blockade therapies (including anti-PD-1, anti-PD-L1, and anti-CTLA4) have become hot topics in cancer immunotherapy in the near past, and their therapeutic value in cancer has been recognized32,33, changing the landscape of cancer treatment34,35. This evidence concerns the gene CD274 and cancer.